WayneMatthewDanknerMD

Infectious Disease • Durham, NC

Adjunct Associate Professor in the Department of Pediatrics, Duke University School of Medicine

Join to view full profile

Dr. Dankner is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Dankner's full profile

Already have an account?

Office
1000 Park Forty Plaza
Suite 360
Durham, NC 27713
Phone+1 919-439-3400

Education & Training

University of California (San Diego) Medical CenterFellowship, Infectious Disease, 1984 - 1987
Stanford Health Care-Sponsored Stanford UniversityResidency, Pediatrics, 1981 - 1984
New York Medical CollegeClass of 1981

Certifications & Licensure

NC State Medical License 2000 - 2025
CA State Medical License 1982 - 2000
American Board of Pediatrics Pediatrics

Clinical Trials

The Safety and Effectiveness of Methylprednisolone in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Children With AIDS
Withdrawn
Phase 3
A Pharmacokinetic and Tolerance Study of Oral Ganciclovir in HIV-Infected Children With Asymptomatic Cytomegalovirus Infection and Low CD4 Cell Counts or Quiescent Cytomegalovirus Disease
Completed
Phase 1
A Study to Compare Different Drugs Used to Prevent Serious Bacterial Infections in HIV-Positive Children
Completed
Phase 2
A Study of Cidofovir in HIV-Infected Children With Cytomegalovirus (CMV) Disease
Withdrawn
Phase 1
A Study on the Rate of Opportunistic (AIDS-Related) Infections Among HIV-Positive Children Who Have Stopped Taking Their OI Preventive Medications
Completed
Not Applicable
Growth Hormone Treatment of Children With HIV-Associated Growth Failure
Completed
Not Applicable
Long-Term Effects of HIV Exposure and Infection in Children
Completed
AZD9773 Dose Escalation Study Start of enrollment: 2008 Jan 01
Completed
Phase 2
A Study to Assess Safety,and Tolerability of 2 Doses of AZD9773 (CytoFab™) in Japanese With Severe Sepsis/Septic Shock Start of enrollment: 2010 Jul 01
Completed
Phase 2
A Study to Compare the Efficacy and Safety of 2 Dosing Regimens of IV Infusions of AZD9773 (CytoFab™) With Placebo in Adult Patients With Severe Sepsis and/or Septic Shock Start of enrollment: 2010 Oct 01
Completed
Phase 2
Phase III Efficacy and Safety Study of AB103 in the Treatment of Patients With Necrotizing Soft Tissue Infections Start of enrollment: 2015 Dec 01
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

14 citations
Estimating the Impact of Necrotizing Soft Tissue Infections in the United States: Incidence and Re-Admissions.
Addison K. May, Victor B. Talisa, David A. Wilfret, Eileen M. Bulger, Wayne Dankner
Surgical Infections. 2021-05-18
22 citations
A Novel Immune Modulator for Patients With Necrotizing Soft Tissue Infections (NSTI): Results of a Multicenter, Phase 3 Randomized Controlled Trial of Reltecimod (AB 103)
Eileen M. Bulger, Addison K. May, Bryce R.H. Robinson, David C. Evans, Sharon Henry
Annals of Surgery. 2020-07-08
12 citations
Validation of a clinical trial composite endpoint for patients with necrotizing soft tissue infections.
Eileen M. Bulger, Addison K. May, Wayne Dankner, Gregory Maislin, Bryce R.H. Robinson
The Journal of Trauma and Acute Care Surgery. 2017-10-01

Press Mentions

Microbion Announces Positive Topline Results from Phase 2 Study of Topical Pravibismane for Moderately Infected Diabetic Foot UlcersNovember 13th, 2024